Key Highlights
- Sun Pharma announced on 19 abstracts to be presented across psoriasis, alopecia areata, and acne portfolios.
- New real-world and long-term data shared for ILUMYA®, LEQSELVI™, and WINLEVI®.
- Focus on patient-centered outcomes and clinical decision-making insights.
Sun Pharma, a leading pharmaceutical company, announced it will present 19 abstracts, including new clinical and real-world findings, at the 2026 Winter Clinical Miami meeting, taking place February 27-March 1 in Aventura, Florida. The data span the company’s dermatology and immunology portfolio, reinforcing its focus on generating meaningful evidence across chronic skin and autoimmune conditions.
According to Ahmad Naim, MD, Senior Vice President and North American Chief Medical Officer, the presentations reflect the company’s patient-first approach in advancing evidence for alopecia areata, plaque psoriasis, and acne. He emphasized that continued scientific research plays a critical role in informing treatment decisions for dermatology clinicians.
ILUMYA® (tildrakizumab-asmn): Expanding Real-World Psoriasis Evidence
ILUMYA data at the conference will include new real-world analyses examining biologic use patterns and continuity of care in patients with moderate-to-severe plaque psoriasis, particularly among older and clinically complex Medicare populations.
Additional presentations evaluate real-world effectiveness, treatment persistence, and patient-reported outcomes across different geographic regions and prior biologic experience. These findings aim to provide practical insights into how ILUMYA performs outside controlled clinical trial settings, reflecting everyday dermatology practice in the United States.
ILUMYA is approved for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It works by selectively targeting the IL-23 pathway, a key driver of inflammatory processes in psoriasis.
LEQSELVI™ (deuruxolitinib): Advancing Treatment in Severe Alopecia Areata
LEQSELVI will be featured in 10 abstracts, highlighting data that demonstrate early and sustained scalp hair regrowth in patients with severe alopecia areata.
Pooled analyses from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials show consistent efficacy across subgroups, including patients with varying disease durations and those with eyebrow, eyelash, and nail involvement. Additional findings explore maintenance of hair regrowth following dose reduction or discontinuation.
The company will also present results from a landmark survey examining discrepancies between patient and clinician perspectives on treatment priorities, awareness, and disease impact, offering broader insight into unmet needs in alopecia areata care.
LEQSELVI is an oral JAK1/JAK2 inhibitor approved for adults with severe alopecia areata.
WINLEVI® (clascoterone cream 1%): Supporting Inclusive Acne Care
WINLEVI data will include new 52-week open-label findings from a pilot study in patients with skin of color, demonstrating sustained improvements in acne severity with a consistent safety and tolerability profile.
Combination studies presented at the meeting show that integrating WINLEVI into multimodal acne regimens, alongside clindamycin/benzoyl peroxide or adapalene, may enhance treatment outcomes. Additional data highlight reductions in facial sebum production following long-term treatment.
WINLEVI is a topical androgen receptor inhibitor indicated for acne vulgaris in patients aged 12 and older.
Strengthening Specialty Dermatology Leadership
As the world’s leading specialty generics company, Sun Pharmaceutical Industries continues to expand its global specialty portfolio, particularly in dermatology and immunology.
The breadth of data presented at Winter Clinical Miami underscores the company’s commitment to delivering robust clinical evidence and real-world insights to support dermatologists in optimizing patient outcomes across chronic skin diseases.
